CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that its CEO Renée Aguiar-Lucander will exercise warrants granted pursuant to Calliditas’ Warrant Program 2017/2020, which corresponds to an investment totaling SEK 15.7 million. Following the exercise, Ms. Aguiar-Lucander’s total shareholding in Calliditas corresponds to 412,000 shares.For further information, please contact: Renée Aguiar-Lucander, CEO, Calliditas Email: renee.lucander@calliditas.com Telephone: +46 722 52 10 06 Mikael Widell, Head of Communications Email: mikael.widell@calliditas.com